Structure of BTK kinase domain with the second-generation inhibitors acalabrutinib and tirabrutinib.
Bruton's tyrosine kinase (BTK) is the target of the therapeutic agent, Ibrutinib, that treats chronic lymphocyte leukemia (CLL), mantle cell lymphoma (MCL) and other B cell malignancies. Ibrutinib is a first in class, covalent BTK inhibitor that limits B-cell survival and proliferation. Designing ne...
Tallennettuna:
| Päätekijät: | , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Public Library of Science (PLoS)
2023-01-01
|
| Sarja: | PLoS ONE |
| Linkit: | https://doi.org/10.1371/journal.pone.0290872 |
| Tagit: |
Ei tageja, Lisää ensimmäinen tagi!
|